A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

This study is testing a new combination treatment using BNT326 and BNT323 — two antibody-drug conjugates that deliver chemotherapy directly to cancer cells — for people with advanced non-small cell lung cancer (NSCLC). Different combinations and patient groups are being studied across multiple treatment parts. **You may be eligible if...** - You are 18 years or older with advanced (metastatic or locally recurrent) non-small cell lung cancer that cannot be treated with curative intent - You have measurable disease on imaging - Your physical condition is good (ECOG 0-1) - Your organ function meets required levels - Tumor tissue is available for testing - Depending on the cohort: you may need to have progressed on prior therapy, or have specific genetic markers **You may NOT be eligible if...** - You have active brain metastases requiring treatment - You have had prior treatment with the specific drugs being tested - You have significant heart, lung, or autoimmune conditions - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.